Eioncell Co. Ltd. and Hallym University have reported new antibody-drug conjugates (ADCs) comprising an antibody targeting kita-kyushu lung cancer antigen 1 (KK-LC-1; CT83) linked to a cytotoxic drug potentially useful for the treatment of cancer.